Receptos to Hold Fourth Quarter and Year End 2014 Financial Results Conference Call
26 févr. 2015 08h00 HE
|
Receptos, Inc.
SAN DIEGO, Feb. 26, 2015 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, will review...
Receptos Announces Oral Podium Presentation at Annual Meeting of European Crohn's and Colitis Organization (ECCO)
18 févr. 2015 08h00 HE
|
Receptos, Inc.
- Detailed Results of Positive Phase 2 Trial of RPC1063 in Ulcerative Colitis to be Presented on February 21, 2015 -
- Company to Host Investor Call and Webcast on February 23, 2015 -
SAN DIEGO,...
Receptos to Present at Leerink Global Healthcare Conference
09 févr. 2015 08h00 HE
|
Receptos, Inc.
SAN DIEGO, Feb. 9, 2015 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today...
Receptos Initiates SUNBEAM Phase 3 Trial of RPC1063 in Relapsing Multiple Sclerosis
22 déc. 2014 08h00 HE
|
Receptos, Inc.
– Following Positive Phase 2 Results, Receptos Now Enrolling Two Phase 3 Trials in Relapsing Multiple Sclerosis –
– Receptos Well...
Receptos Announces Full Exercise of Underwriters' Option to Purchase Additional Shares and Completion of Underwritten Public Offering of Common Stock
24 nov. 2014 09h48 HE
|
Receptos, Inc.
SAN DIEGO, Nov. 24, 2014 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, announced...
Receptos Announces Pricing of Underwritten Public Offering of Common Stock
18 nov. 2014 20h10 HE
|
Receptos, Inc.
SAN DIEGO, Nov. 18, 2014 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, announced...
Receptos Announces Proposed Underwritten Public Offering of Common Stock
17 nov. 2014 16h01 HE
|
Receptos, Inc.
SAN DIEGO, Nov. 17, 2014 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, announced...
Receptos to Present at Credit Suisse Healthcare Conference
06 nov. 2014 16h01 HE
|
Receptos, Inc.
SAN DIEGO, Nov. 6, 2014 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today...
Receptos Provides Development Updates and Reports Third Quarter 2014 Financial Results
04 nov. 2014 07h00 HE
|
Receptos, Inc.
- Recent positive Phase 2 induction results for TOUCHSTONE trial of RPC1063 in ulcerative colitis (UC) support initiation of broad program in inflammatory bowel disease -
- Enrollment in first...
Receptos to Present at Nomura BioPharma Conference
03 nov. 2014 16h01 HE
|
Receptos, Inc.
SAN DIEGO, Nov. 3, 2014 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today...